Adjuvant therapy for very young women with breast cancer: Response according to biologic and endocrine features

Clinical Breast Cancer

Volumn 5, Issue 2, 2004, Pages 125-130

  Curigliano, Giuseppe ^a   Rigo, Rodrigo ^a   Colleoni, Marco ^a   de Braud, Filippo ^a   Nolè, Franco ^a   Formica, Vincenzo ^a   Orlando, Laura ^a   Cinieri, Saverio ^a   Torrisi, Rosalba ^a   Cardillo, Anna ^a   Peruzzotti, Giulia ^a   Medici, Marta ^a   Ardito, Raffaelle ^a   Minchella, Ida ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Amenorrhea; Chemotherapy; Endocrine therapy; Estrogen receptor; Premenopausal patients; Progesterone receptor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; AMENORRHEA; ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL; DATA ANALYSIS; DISEASE ACTIVITY; DRUG CHOICE; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ESTROGEN DEFICIENCY; FEMALE; GERIATRIC PATIENT; GROUPS BY AGE; HUMAN; MEDICAL DECISION MAKING; PREMENOPAUSE; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; TREATMENT PLANNING; VAGINAL DRYNESS; VASOMOTOR DISORDER;

EID: 3543084604     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.016     Document Type: Article

References (36)

1. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use CD ROM (1973-1997), National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, released April 2000, based on the August 1999 submission.
2. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355:1869-1874.
3. Walker RA, Lees E, Webb MB, et al. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996; 74:1796-1800.
4. Chung M, Chang HR, Bland KI, et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996; 77:97-103.
5. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002; 13:273-279.
6. Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 1996; 78:1838-1843.
7. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996;14:1885-1894.
8. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985; 45:4454-4459.
9. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988; 319:677-683.
10. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001; 30:44-51.
11. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990; 1:183-188.
12. Nystedt M, Berglund G, Bolund C et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 2003; 21:1836-1844.
13. Adami HO, Malker B, Holmberg L, et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315:559-563.
14. Kollias J, Elston CW, Ellis IO, et al. Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 1997; 75:1318-1323.
15. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994; 16:69-77.
16. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer 1997; 33:425-428.
17. Jeng MH, Shupnik MA, Bender TP et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinol 1998; 139:4164-4174.
18. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-1481.
19. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34:632-640.
20. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. Br Med J 2000; 320:474-478.
21. Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985; 3:1059-1067.
22. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312:665-673.
23. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with and without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456-1461.
24. Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981; 305:1-6.
25. Wickerham D, Fisher B, Cronin W. The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Res Treat 1984; 4:303-307.
26. Fisher B, Wickerham D, Redmond C, et al. Increased benefit from addition of adriamycin to adjuvant therapy for stage II breast cancer: results from NSABP protocols B-11 and -12. Proc Am Soc Clin Oncol 1987; 6:62 (Abstract #62)
27. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8:1483-1496.
28. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8:1005-1018.
29. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15:1858-1869.
30. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17:3374-3388.
31. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
32. Merkel D. Pregnancy and breast cancer. Semin Surg Oncol 1996; 12:370-375
33. Liberman L, Giess C, Dershaw D, et al. Imaging of pregnancy-associated breast cancer. Radiology 1994; 191:245-248.
34. Elledge R, Ciocca D, Langone G, et al. Estrogen receptor, progesterone receptor and HER-2/neu protein in breast cancers from pregnant patients. Cancer 1993; 71:2499-2506.
35. Guinee VF, Olsson H, Moller T, et al. Effect of pregnancy on prognosis for young women with breast cancer. Lancet 1994; 343:1587-1589.
36. Williams S, Schilsky R. Antineoplastic drugs administred during pregnancy. Semin Oncol 2000; 27:618-622.